|
Interferon alfa-n1
drug data and news
Interferon alfa-n1 drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Interferon alfa-n1
|
| Brand Names/Synonyms |
Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Wellferon (GlaxoSmithKline) |
| Indication |
For treatment of venereal or genital warts caused by the Human Papiloma Virus |
|
Sponsored links
|
|
Description |
Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues |
| Pharmacology |
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. |
| Mechanism Of Action |
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. |
Interferon alfa-n1 News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
LIQUID |
| Drug_Category |
Antiviral Agents; Immunomodulatory Agents; antineoplastic agents (10:00.00) |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Not Available |
| Chemical IUPAC Name |
Human interferon alpha |
| Chemical Formula |
C860H1353N227O255S9 |
| Molecular Weight |
19241.1 |
| Smiles String |
Not Available |
| Melting Point |
Melting point: 61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)) Davis JM, Narachi MA, Levine HL, Alton NK, Arakawa T. Conformation and stability of two recombinant human interferon-alpha analogs. Int J Pept Protein Res. 1987 Jun;29(6):685-91. |
| Water Solubility |
Not Available |
| State |
Transparent, slightly viscous, aqueous liquid |
| LogP/Hphobicity |
-0.336 |
| Isoelectric Point |
5.99 |
| Biotransformation |
Not Available |
| Half Life |
1.2 hours (mammalian reticulocytes, in vitro). >20 hours (yeast, in vivo). >10 hours (Escherichia coli, in vivo). |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
BIOD00096 |
| CAS Registry Number |
74899-72-2; 9008-11-1 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
Not Available |
| PharmGKB ID |
PA10274 |
| SwissProt ID |
IFNA2_HUMAN (P01563) |
| GenBank ID |
J00207 |
| Drug ID Number [DIN] |
1959077
|
|
|
